JAK/STAT signaling in hepatocellular carcinoma
Liver cancer is the second most lethal cancer in the world with limited treatment options. Hepatocellular carcinoma (HCC), which accounts for more than 80% of all liver cancers, has had increasing global incidence over the past few years. There is an urgent need for novel and better therapeutic inte...
Saved in:
| Main Authors: | Justin Jit Hin Tang, Dexter Kai Hao Thng, Jhin Jieh Lim, Tan Boon Toh |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis
2020-03-01
|
| Series: | Hepatic Oncology |
| Subjects: | |
| Online Access: | https://www.futuremedicine.com/doi/10.2217/hep-2020-0001 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
JAK/STAT signaling as a key regulator of ferroptosis: mechanisms and therapeutic potentials in cancer and diseases
by: Yimeng Dai, et al.
Published: (2025-03-01) -
EPHX1 enhances drug resistance to regorafenib by activating the JAK/STAT signaling pathway in hepatocellular carcinoma cell lines
by: Bin Xu, et al.
Published: (2025-07-01) -
JAK-STAT inhibitors in noninfectious uveitis – A review
by: Richa Pyare, et al.
Published: (2025-06-01) -
Identification of key molecular targets for stachyose in hepatocellular carcinoma: focus on STAT3 and FN1
by: Haihua Chen, et al.
Published: (2025-07-01) -
The Hyperactivation of JAK-STAT Signaling Connects Inborn Errors of Immunity and Autoimmune Diseases
by: JIANG Yi, et al.
Published: (2024-10-01)